Liquidia surges as United Therapeutics settlement removes key litigation risk
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Liquidia shares surged after a settlement announced late on Tuesday ended six lawsuits with United Therapeutics.
- ✓Liquidia will pay $380.7 million by 2027 and stop promoting its drug Yutrepia for PH-ILD.
- ✓CFO Michael Kaseta said, "We expect to fund the outlined payments from the ongoing sales of Yutrepia and cash."
Story at a Glance
- Category
- BUSINESS
- Reported By
- Reuters
- Reading Speed
- 2 Minute(s)
- Market Focus
- India Economy
The settlement, announced late on Tuesday, ends six lawsuits over patents, trade secrets, contracts and antitrust claims related to Liquidia's Yutrepia, an inhaled dry-powder form of the drug treprostinil.
Sign up here.
Yutrepia is approved to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), and competes in the market with United Therapeutics' Tyvaso.
As part of the settlement, Liquidia will stop promoting its drug for PH-ILD, but will keep selling it for PAH. It will also pay United Therapeutics about $380.7 million in installments through 2027.
"We expect to fund the outlined payments from the ongoing sales of Yutrepia and cash on hand," Chief Financial Officer Michael Kaseta said.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Reuters
Read the full, original unfiltered story directly on the publisher's portal.